Extension study for people continuing ASTX727 from a prior trial
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This study checks whether continuing ASTX727 for people who already benefited from it in an earlier Taiho study is safe and effective. It may be an option if you stayed on ASTX727 at the end of your parent study and your doctor felt it was helping you.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have taken ASTX727 in a previous Taiho/Astex ASTX727 study and were still on it when that study ended
- Your doctor must think ASTX727 was helping you at the time the earlier study finished
- You must be able to understand the study and follow its visit and procedure schedule
- You must sign consent before any study-specific testing happens
- If you can become pregnant: you must not be pregnant or breastfeeding and must use reliable birth control during the study and for 6 months after the last dose
- If you have a female partner who can become pregnant: you must use reliable contraception and not father a child during treatment and for at least 3 months after
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase study tests CTX-712, a new cancer treatment, in people whose acute myeloid leukemia (AML) or certain high-risk blood cancers came back or did not respond to prior therapy. It may help shrink the cancer and control the disease by targeting it differently than standard treatments.
This trial allows people who were already getting study treatment in a previous trial to keep receiving it and be monitored for safety. It is designed for those who have not had serious side effects or disease worsening.
This early-phase study tests a new drug called STX-0712 for people with certain types of blood cancers (CMML or AML) that have not responded to standard treatments. The goal is to see if the drug is safe and can help shrink or control the cancer.
This trial tests a new drug, STX-721, for people with advanced non-small cell lung cancer that has a specific genetic change (EGFR or HER2 exon 20 insertion). The study aims to see if the drug is safe and effective.
This study tests whether adding a new drug called iadademstat to the standard treatment ASTX727 helps people with advanced myeloproliferative neoplasms (blood cancers that cause the bone marrow to make too many cells). The goal is to see if the combination is safe and works better than the standard treatment alone.
This study allows people who are already in a Daiichi Sankyo trial and getting benefit from the study drug to continue receiving it safely. It monitors long-term safety for those who have not had their cancer worsen.
Hear when a new Acute Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.